<DOC>
	<DOCNO>NCT00655655</DOCNO>
	<brief_summary>RATIONALE : Everolimus vatalanib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Giving everolimus together vatalanib may kill tumor cell . PURPOSE : This phase I trial study side effect best dose everolimus vatalanib treat patient advance solid tumor .</brief_summary>
	<brief_title>Everolimus Vatalanib Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . To determine dose limit toxicity ( DLT ) maximally tolerate dose ( MTD ) RAD001 daily PTK787 give combination . ( Cohort IA ) II . To describe toxicity associate combination RAD001 daily PTK787 . ( Cohort IA ) III . To evaluate therapeutic antitumor activity combination daily PTK787 RAD001 . ( Cohort IA ) IV . To determine dose limit toxicity ( DLT ) maximally tolerate dose ( MTD ) RAD001 twice daily PTK787 give combination . ( Cohort IB ) V. To describe toxicity associate combination RAD001 twice daily PTK787 . ( Cohort IB ) VI . To evaluate therapeutic antitumor activity combination twice daily PTK787 RAD001 . ( Cohort IB ) VII . To determine MTD-Recommended Phase 2 Dose ( RP2D ) base MTD Cohorts IA IB . ( Cohorts IA &amp; IB ) VIII . To investigate biological activity combination PTK787 RAD001 MTD-RP2D . ( Cohort II ) IX . To evaluate therapeutic antitumor activity combination PTK787 RAD001 MTD-RP2D . ( Cohort II ) X . To evaluate pharmacogenetic , metabolic clinical marker may predict hypertension induce anti-VEGF therapy . ( Cohort II ) XI . To obtain pilot data efficacy outcomes patient metastatic kidney cancer , neuroendocrine cancer , NSCLC melanoma . ( Cohort II ) OUTLINE : Patients assign 1 4 cohort , accord disease ( cohort IA , IB , IIA [ histopathologic diagnosis ] v cohort IIB [ metastatic kidney cancer , neuroendocrine cancer , melanoma , non-small cell lung cancer ) . Patients initially enrol cohort IA IB maximum tolerate dose ( MTD ) recommend phase II dose ( RP2D ) determine . Once MTD/RP2D everolimus vatalanib determine , subsequent patient enrol treated expansion cohort IIA IIB . Cohorts 1A 1B ( dose escalation cohort ; close enrollment 12/6/06 ) : Patients receive oral vatalanib ( cohort 1A ) twice ( cohort 1B ) daily day 1-28 oral everolimus daily day 15-28 course 1 . For subsequent course , patient receive oral vatalanib ( cohort 1A ) twice ( cohort 1B ) daily oral everolimus daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohort IIA ( expansion cohort treat MTD/RP2D ) : Patients receive oral everolimus daily 14 day follow 7-day rest period . Patients receive oral vatalanib twice daily day 1-28 oral everolimus daily day 15-28 course 1 . For subsequent course , patient receive oral vatalanib twice daily oral everolimus daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohort IIB ( expansion cohort treat MTD/RP2D ) : Patients receive oral vatalanib twice daily day 1-28 oral everolimus daily day 15-28 course 1 . For subsequent course , patient receive oral vatalanib twice daily oral everolimus daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 month .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Islet Cell</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Gastrinoma</mesh_term>
	<mesh_term>Somatostatinoma</mesh_term>
	<mesh_term>Insulinoma</mesh_term>
	<mesh_term>Carcinoma , Medullary</mesh_term>
	<mesh_term>Glucagonoma</mesh_term>
	<mesh_term>Carcinoma , Merkel Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Histologic proof cancer unresectable ( solid tumor , exclude lymphoma ) Ability provide inform consent Willingness return Mayo Clinic Rochester follow Life expectancy &gt; = 12 week Prior antiVEGF therapy allow Cohort IIA : Patients meet eligibility criterion , regardless histopathologic diagnosis ; tumor amenable biopsy ; willingness provide blood specimen , undergo DCEMRI , undergo brachial artery ultrasound measurement require protocol The following laboratory value obtain = &lt; 14 day prior registration : Negative proteinuria base dip stick reading OR , documentation +1 result protein dip stick reading , total urinary protein = &lt; 500 mg measure creatinine clearance ( CrCl ) &gt; = 50 mL/min 24hour urine collection Cohort IIB : Patients meet eligibility criterion AND pathologic diagnosis metastatic kidney cancer , neuroendocrine carcinoma , melanoma , NSCLC ; willingness provide blood specimen require undergo brachial artery ultrasound measurements The following laboratory value obtain = &lt; 14 day prior registration : ANC &gt; = 1500/uL ; Hgb &gt; = 9 g/dL ; PLT &gt; = 100,000/uL ; Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) ; AST = &lt; 3 x ULN AST = &lt; 5 x ULN liver involvement ; Creatinine = &lt; 1.5 x ULN ; INR = &lt; 1.4 ( Cohort IIA ) Any follow prior therapy : Full field radiation therapy = &lt; 4 week prior registration limit field radiation therapy = &lt; 2 week prior registration ; Radiation &gt; 30 % bone marrow ; Major surgery ( i.e. , laparotomy ) = &lt; 4 week prior registration ; Minor surgery = &lt; 2 week prior registration New York Heart Association classification III IV Uncontrolled hypertension , labile hypertension history poor compliance antihypertensive medication Active , bleed diathesis anticoagulant except patient receive heparin deep venous thrombosis prophylaxis ( treatment ) CNS metastases seizure disorder Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( utilized nonFDAapproved indication context research investigation Any concurrent severe and/or uncontrolled medical condition could compromise participation pose unnecessary risk patient study , include , limited , follow : Unstable angina ; Myocardial infarction = &lt; 6 month prior registration ; Serious uncontrolled cardiac arrhythmia ; Uncontrolled diabetes Any concurrent severe and/or uncontrolled medical condition could compromise participation pose unnecessary risk patient study , include , limited , follow : Interstitial pneumonia extensive symptomatic interstitial fibrosis lung ; QTc &gt; 500 msec ; Patients require chronic treatment PPI H2 antagonist Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption PTK787/ZK 222584 ( i.e. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , bowel obstruction , inability swallow tablet ) Known standard therapy patient 's disease potentially curative definitely capable extend life expectancy Chemotherapy = &lt; 3 week ; Mitomycin C/nitrosoureas = &lt; 6 week ; Immunotherapy = &lt; 2 week ; Biologic therapy = &lt; 2 week ; Prior investigational therapy = &lt; 4 week ; Full field radiation therapy = &lt; 4 week limited field radiation therapy = &lt; 2 week ; Radiation &gt; 30 % bone marrow ; Major surgery ( i.e. , laparotomy ) = &lt; 4 week ; Minor surgery = &lt; 2 week prior registration Any following : pregnant woman ; nurse woman ; men woman childbearing potential unwilling employ adequate barrier contraception Patients DCEMRI contraindicate ( e.g. , presence MRIincompatible metallic implant prosthetic heart valve , pacemaker , etc . ) ineligible ECOG performance status ( PS ) 3 4 Treatment medication list Appendix I safer efficacious alternative available Uncontrolled infection Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>